One-dose drug reduced genetic bad cholesterol by 94% for almost a year
Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.
One-dose drug reduced genetic bad cholesterol by 94% for almost a year Read more